Regeneron Pharmaceuticals, Inc. REGN
- Market cap
- $81.3B
- P/E
- 18.8×
Follow REGN
Regeneron Pharmaceuticals, Inc. (REGN) Return on invested capital
Regeneron Pharmaceuticals, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 9.34%, up 0.5 percentage points from fiscal 2025 (8.82%). Over the past ten years it has ranged from 8.82% (fiscal 2025) to 37.1% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Annual
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 8.82% | (2.00) |
| FY2024 | 10.8% | (3.37) |
| FY2023 | 14.2% | (2.62) |
| FY2022 | 16.8% | (20.33) |
| FY2021 | 37.1% | 15.08 |
| FY2020 | 22.1% | 5.98 |
| FY2019 | 16.1% | (7.72) |
| FY2018 | 23.8% | (0.10) |
| FY2017 | 23.9% | 1.79 |
| FY2016 | 22.1% | (4.21) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 60.2% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 24.1% |
| ARGX argenex SE compare | 20.7% |
| REGN Regeneron Pharmaceuticals, Inc. | 9.34% |
| RPRX Royalty Pharma PLC compare | 5.28% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.00% |
| RVMD Revolution Medicines, Inc. compare | 0.00% |
| MRNA Moderna, Inc. compare | −93.5% |
| INSM Insmed, Inc. compare | −329.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on REGN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement